These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer]. Protasov DA, Zel'dovich DR, Kuz'mina LP, Manikhas GM. Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973 [Abstract] [Full Text] [Related]
6. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen. Jelić S, Radulović S, Nesković-Konstantinović Z, Kreacić M, Ristović Z, Bosnjak S, Milanović N, Vuletić L. Support Care Cancer; 1995 May; 3(3):176-82. PubMed ID: 7655778 [Abstract] [Full Text] [Related]
10. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E. Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894 [Abstract] [Full Text] [Related]
14. Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin. de Bree E, van Ruth S, Schotborgh CE, Baas P, Zoetmulder FA. Ann Surg Oncol; 2007 Oct; 14(10):3019-26. PubMed ID: 17638057 [Abstract] [Full Text] [Related]